Add BrightSurf on Google Email

Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies

Home | Story
2 institutional releases

Published in Molecular Psychiatry · View the paper (DOI)

A new study suggests that spironolactone, a medication for heart problems and high blood pressure, may also be effective in reducing alcohol drinking. The research found that increasing doses of spironolactone decreased alcohol consumption in mice and rats, as well as in humans with excessive alcohol drinking.

Coverage from 2 institutions

  • Heart medication shows potential as treatment for alcohol use disorder
    • Article 1 NIH/National Institute on Drug Abuse · Sep 19, 2022 · first to report
    • Article 2 NIH/National Institute on Alcohol Abuse and Alcoholism · Sep 19, 2022